Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients.

Humans Behcet Syndrome / complications Tumor Necrosis Factor Inhibitors / therapeutic use Treatment Outcome Uveitis / etiology Antirheumatic Agents / therapeutic use Tumor Necrosis Factor-alpha Retrospective Studies
Behçet disease neuro-Behçet tocilizumab uveitis

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
07 2023
Historique:
accepted: 25 01 2023
medline: 5 7 2023
pubmed: 2 3 2023
entrez: 1 3 2023
Statut: ppublish

Résumé

To evaluate tocilizumab (TCZ) efficacy in patients with refractory Behçet disease (BD). This is a multicenter study of 30 patients fulfilling the international criteria for BD and treated with TCZ at different European referral centers. The clinical response was evaluated at 6 months from TCZ initiation. Ninety percent of patients with BD were refractory or intolerant to anti-tumor necrosis factor (anti-TNF) agents. Overall, TCZ was effective in 25 (83%) patients with BD of whom 18 (60%) and 7 (23%) were complete and partial responders, respectively. The complete response was 67%, 60%, and 42% in patients with uveitis (18/30), neurological manifestations (5/30), and mucocutaneous and/or articular (7/30) manifestations, respectively. TCZ had a significant steroid-sparing effect allowing patients to decrease their median daily prednisone dose from 20 (IQR 10-40) mg/day to 9 (IQR 5-13) mg at 6 months ( TCZ seems to be an effective alternative to anti-TNF agents in treating BD-related uveitis and neurological manifestations.

Identifiants

DOI: 10.3899/jrheum.221106 PMID: 36858435
pubmed: 36858435
pii: jrheum.221106
doi: 10.3899/jrheum.221106
doi:

Substances chimiques

tocilizumab I031V2H011
Tumor Necrosis Factor Inhibitors 0
Antirheumatic Agents 0
Tumor Necrosis Factor-alpha 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

916-923

Informations de copyright

Copyright © 2023 by the Journal of Rheumatology.

Auteurs

Mohamed-Yacine Khitri (MY)

M.Y. Khitri, MD, A. Bartoli, MD, G. Maalouf, MD, M. Vautier, MD, P. Cacoub, MD, PhD, D. Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Paris, France.
ORCID: 0000-0002-2090-5750

Alessandra Bartoli (A)

M.Y. Khitri, MD, A. Bartoli, MD, G. Maalouf, MD, M. Vautier, MD, P. Cacoub, MD, PhD, D. Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Paris, France.

Georgina Maalouf (G)

M.Y. Khitri, MD, A. Bartoli, MD, G. Maalouf, MD, M. Vautier, MD, P. Cacoub, MD, PhD, D. Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Paris, France.

Alban Deroux (A)

A. Deroux, MD, Department of Internal Medicine, University Hospital of Grenoble, Grenoble, France.

Carlo Salvarani (C)

C. Salvarani, MD, PhD, Division of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Modena and Reggio Emilia, Italy.

Giacomo Emmi (G)

G. Emmi, MD, PhD, Department of Experimental and Clinical Medicine, University of Florence, Florence, Behçet Centre, Careggi University Hospital, Florence, Italy, and Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.

Omer Karadag (O)

O. Karadag, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Vasculitis Research Center, Hacettepe University School of Medicine, Ankara, Turkey.
ORCID: 0000-0002-3443-3117

Gerard Espinosa (G)

G. Espinosa, MD, PhD, Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
ORCID: 0000-0003-1336-0163

Mathilde Leclercq (M)

M. Leclercq, MD, Internal Medicine Department, CHU Rouen, Rouen, France.

Gabriele Simonini (G)

G. Simonini, MD, Rheumatology Unit, NEUROFARBA Department, Meyer Children's Hospital, University of Florence, Florence, Italy.

Mathieu Vautier (M)

M.Y. Khitri, MD, A. Bartoli, MD, G. Maalouf, MD, M. Vautier, MD, P. Cacoub, MD, PhD, D. Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Paris, France.

Patrice Cacoub (P)

M.Y. Khitri, MD, A. Bartoli, MD, G. Maalouf, MD, M. Vautier, MD, P. Cacoub, MD, PhD, D. Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Paris, France.

David Saadoun (D)

M.Y. Khitri, MD, A. Bartoli, MD, G. Maalouf, MD, M. Vautier, MD, P. Cacoub, MD, PhD, D. Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Paris, France; david.saadoun@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vasculaires › Maladie de Behçet › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-inflammatoires › Inhibiteurs du facteur de nécrose tumorale › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Maladies de l'oeil › Maladies de l'uvée › Uvéite › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Tocilizumab in Behçet Disease: A Multicenter...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Tocilizumab in Behçet Disease: A Multicenter...